Published • loading... • Updated
Apnimed Announces Pricing of Upsized Initial Public Offering
The company expects $192 million in gross proceeds to fund development of its sleep apnea drug AD109.
- Apnimed priced its upsized initial public offering at $16 per share today, with common stock beginning to trade on the Nasdaq Global Select Market under ticker "APMD".
- Cambridge, Massachusetts-based Apnimed is advancing AD109, a candidate for obstructive sleep apnea that has completed two Phase 3 clinical trials addressing sleep-related breathing diseases.
- The offering is expected to generate $192 million in gross proceeds, with BofA Securities, Evercore ISI, Cantor, and LifeSci Capital serving as joint book-running managers.
- Following the pricing announcement, the company expects the offering to close on or about August 3, 2026, subject to customary closing conditions.
- Registration statements filed with the Securities and Exchange Commission became effective July 30, 2026, while AD109's New Drug Application carries a Prescription Drug User Fee Act goal date of February 28, 2027.
Insights by Ground AI
47 Articles
47 Articles
Shionogi-Backed Biotech Apnimed Raises $192 Million in US IPO
·New York, United States
Read Full Article
Apnimed Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of…
·Indiana, United States
Read Full Article
Coverage Details
Total News Sources47
Leaning Left5Leaning Right4Center34Last UpdatedBias Distribution79% Center
Bias Distribution
- 79% of the sources are Center
79% Center
12%
C 79%
Factuality
To view factuality data please Upgrade to Premium
